{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:19:24Z","timestamp":1786979964515,"version":"build-2736575974"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T00:00:00Z","timestamp":1647648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T00:00:00Z","timestamp":1647648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s00296-022-05108-1","type":"journal-article","created":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T23:02:37Z","timestamp":1647644557000},"page":"1133-1142","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Evaluation of flare rate and reduction strategies for bDMARDs in juvenile idiopathic arthritis: real world data from a single-centre cohort"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3670-6796","authenticated-orcid":false,"given":"Ant\u00eda","family":"Garc\u00eda-Fern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9149-7355","authenticated-orcid":false,"given":"Andrea","family":"Briones-Figueroa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3806-1488","authenticated-orcid":false,"given":"Laura","family":"Calvo-Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1frica","family":"Andreu-Su\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7826-6947","authenticated-orcid":false,"given":"Alina","family":"Boteanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,19]]},"reference":[{"key":"5108_CR1","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/S0140-6736(11)60244-4","volume":"377","author":"B Prakken","year":"2011","unstructured":"Prakken B, Albani S, Martini A (2011) Juvenile idiopathic arthritis. Lancet 377:2138\u20132149. https:\/\/doi.org\/10.1016\/S0140-6736(11)60244-4","journal-title":"Lancet"},{"key":"5108_CR2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1097\/BOR.0000000000000727","volume":"32","author":"IR Klein-Wieringa","year":"2020","unstructured":"Klein-Wieringa IR, Brinkman DMC, ten Cate R, Hissink Muller PCE (2020) Update on the treatment of nonsystemic juvenile idiopathic arthritis including treatment-to-target: is (drug-free) inactive disease already possible? Curr Opin Rheum 32:403\u2013413. https:\/\/doi.org\/10.1097\/BOR.0000000000000727","journal-title":"Curr Opin Rheum"},{"key":"5108_CR3","doi-asserted-by":"publisher","first-page":"5860","DOI":"10.2174\/0929867325666180522085716","volume":"25","author":"D Poddighe","year":"2019","unstructured":"Poddighe D, Romano M, Gattinara M, Gerloni V (2019) Biologics for the treatment of juvenile idiopathic arthritis. Curr Med Chem 25:5860\u20135893. https:\/\/doi.org\/10.2174\/0929867325666180522085716","journal-title":"Curr Med Chem"},{"key":"5108_CR4","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1136\/annrheumdis-2018-213030","volume":"77","author":"A Ravelli","year":"2018","unstructured":"Ravelli A, Consolaro A, Horneff G et al (2018) Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis 77:819\u2013828. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213030","journal-title":"Ann Rheum Dis"},{"key":"5108_CR5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jbspin.2015.03.005","volume":"83","author":"J Wipff","year":"2016","unstructured":"Wipff J, Sparsa L, Lohse A et al (2016) Impact of juvenile idiopathic arthritis on quality of life during transition period at the era of biotherapies. Joint Bone Spine 83:69\u201374. https:\/\/doi.org\/10.1016\/j.jbspin.2015.03.005","journal-title":"Joint Bone Spine"},{"key":"5108_CR6","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00296-020-04774-3","volume":"41","author":"F Thiele","year":"2021","unstructured":"Thiele F, Klein A, Windschall D et al (2021) Comparative risk of infections among real-world users of biologics for juvenile idiopathic arthritis: data from the German BIKER registry. Rheumatol Int 41:751\u2013762. https:\/\/doi.org\/10.1007\/s00296-020-04774-3","journal-title":"Rheumatol Int"},{"key":"5108_CR7","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.3899\/jrheum.100219","volume":"37","author":"A Remesal","year":"2010","unstructured":"Remesal A, de Inocencio J, Merino R, Garcia-Consuegra J (2010) Discontinuation of etanercept after successful treatment in patients with juvenile idiopathic arthritis. J Rheumatol 37:1970\u20131971. https:\/\/doi.org\/10.3899\/jrheum.100219","journal-title":"J Rheumatol"},{"key":"5108_CR8","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s00296-013-2884-z","volume":"34","author":"E Iglesias","year":"2014","unstructured":"Iglesias E, Torrente-Segarra V, Bou R et al (2014) Non-systemic juvenile idiopathic arthritis outcome after reaching clinical remission with anti-TNF-\u03b1 therapy: a clinical practice observational study of patients who discontinued treatment. Rheumatol Int 34:1053\u20131057. https:\/\/doi.org\/10.1007\/s00296-013-2884-z","journal-title":"Rheumatol Int"},{"key":"5108_CR9","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/acr.22477","volume":"67","author":"CY Chang","year":"2015","unstructured":"Chang CY, Meyer RML, Reiff AO (2015) Impact of medication withdrawal method on flare-free survival in patients with juvenile idiopathic arthritis on combination therapy: medication withdrawal method in JIA. Arthritis Care Res (Hoboken) 67:658\u2013666. https:\/\/doi.org\/10.1002\/acr.22477","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"5108_CR10","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1007\/s00296-012-2468-3","volume":"33","author":"J Post\u0119pski","year":"2013","unstructured":"Post\u0119pski J, Kobusi\u0144ska K, Olesi\u0144ska E et al (2013) Clinical remission in juvenile idiopathic arthritis after termination of etanercept. Rheumatol Int 33:2657\u20132660. https:\/\/doi.org\/10.1007\/s00296-012-2468-3","journal-title":"Rheumatol Int"},{"key":"5108_CR11","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1007\/s00296-012-2642-7","volume":"33","author":"Y Cai","year":"2013","unstructured":"Cai Y, Liu X, Zhang W et al (2013) Clinical trial of etanercept tapering in juvenile idiopathic arthritis during remission. Rheumatol Int 33:2277\u20132282. https:\/\/doi.org\/10.1007\/s00296-012-2642-7","journal-title":"Rheumatol Int"},{"key":"5108_CR12","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1136\/ard.2011.150193","volume":"70","author":"MW Heijstek","year":"2011","unstructured":"Heijstek MW, Ott de Bruin LM, Bijl M et al (2011) EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis 70:1704\u20131712. https:\/\/doi.org\/10.1136\/ard.2011.150193","journal-title":"Ann Rheum Dis"},{"key":"5108_CR13","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1002\/art.40509","volume":"70","author":"DJ Lovell","year":"2018","unstructured":"Lovell DJ, Johnson AL, Huang B et al (2018) Risk, timing, and predictors of disease flare after discontinuation of anti-tumor necrosis factor therapy in children with polyarticular forms of juvenile idiopathic arthritis with clinically inactive disease. Arthritis Rheumatol 70:1508\u20131518. https:\/\/doi.org\/10.1002\/art.40509","journal-title":"Arthritis Rheumatol"},{"key":"5108_CR14","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1002\/art.30502","volume":"63","author":"K Baszis","year":"2011","unstructured":"Baszis K, Garbutt J, Toib D et al (2011) Clinical outcomes after withdrawal of anti-tumor necrosis factor \u03b1 therapy in patients with juvenile idiopathic arthritis: a twelve-year experience: withdrawal of anti-TNF\u03b1 therapy in JIA. Arthritis Rheum 63:3163\u20133168. https:\/\/doi.org\/10.1002\/art.30502","journal-title":"Arthritis Rheum"},{"key":"5108_CR15","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1002\/acr.23435","volume":"70","author":"G Simonini","year":"2018","unstructured":"Simonini G, Ferrara G, Pontikaki I et al (2018) Flares after withdrawal of biologic therapies in juvenile idiopathic arthritis: clinical and laboratory correlates of remission duration. Arthritis Care Res (Hoboken) 70:1046\u20131051. https:\/\/doi.org\/10.1002\/acr.23435","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"5108_CR16","doi-asserted-by":"publisher","first-page":"956","DOI":"10.3899\/jrheum.170794","volume":"45","author":"A Aquilani","year":"2018","unstructured":"Aquilani A, Marafon DP, Marasco E et al (2018) Predictors of flare following etanercept withdrawal in patients with rheumatoid factor\u2013negative juvenile idiopathic arthritis who reached remission while taking medication. J Rheumatol 45:956\u2013961. https:\/\/doi.org\/10.3899\/jrheum.170794","journal-title":"J Rheumatol"},{"key":"5108_CR17","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40272-019-00362-6","volume":"21","author":"O Halyabar","year":"2019","unstructured":"Halyabar O, Mehta J, Ringold S et al (2019) Treatment withdrawal following remission in juvenile idiopathic arthritis: a systematic review of the literature. Pediatr Drugs 21:469\u2013492. https:\/\/doi.org\/10.1007\/s40272-019-00362-6","journal-title":"Pediatr Drugs"},{"key":"5108_CR18","first-page":"2290","volume":"31","author":"CA Wallace","year":"2004","unstructured":"Wallace CA, Ruperto N, Giannini E (2004) Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 31:2290\u20132294","journal-title":"J Rheumatol"},{"key":"5108_CR19","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1136\/annrheumdis-2014-207164","volume":"75","author":"J Guzman","year":"2016","unstructured":"Guzman J, Oen K, Huber AM et al (2016) The risk and nature of flares in juvenile idiopathic arthritis: results from the ReACCh-Out cohort. Ann Rheum Dis 75:1092\u20131098. https:\/\/doi.org\/10.1136\/annrheumdis-2014-207164","journal-title":"Ann Rheum Dis"},{"key":"5108_CR20","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1136\/ard.2008.101030","volume":"68","author":"FHM Prince","year":"2009","unstructured":"Prince FHM, Twilt M, Simon SCM et al (2009) When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis. Ann Rheum Dis 68:1228\u20131229. https:\/\/doi.org\/10.1136\/ard.2008.101030","journal-title":"Ann Rheum Dis"},{"key":"5108_CR21","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1007\/s10067-017-3682-x","volume":"36","author":"Y Su","year":"2017","unstructured":"Su Y, Yang Y-H, Chiang B-L (2017) Treatment response to etanercept in methotrexate refractory juvenile idiopathic arthritis: an analysis of predictors and long-term outcomes. Clin Rheumatol 36:1997\u20132004. https:\/\/doi.org\/10.1007\/s10067-017-3682-x","journal-title":"Clin Rheumatol"},{"key":"5108_CR22","first-page":"919","volume":"28","author":"P Pratsidou-Gertsi","year":"2010","unstructured":"Pratsidou-Gertsi P, Trachana M, Pardalos G, Kanakoudi-Tsakalidou F (2010) A follow-up study of patients with juvenile idiopathic arthritis who discontinued etanercept due to disease remission. Clin Exp Rheumatol 28:919\u2013922","journal-title":"Clin Exp Rheumatol"},{"key":"5108_CR23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1136\/annrheumdis-2018-213902","volume":"78","author":"P Hissink Muller","year":"2019","unstructured":"Hissink Muller P, Brinkman DMC, Schonenberg-Meinema D et al (2019) Treat to target (drug-free) inactive disease in DMARD-naive juvenile idiopathic arthritis: 24-month clinical outcomes of a three-armed randomised trial. Ann Rheum Dis 78:51\u201359. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213902","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-022-05108-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-022-05108-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-022-05108-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T05:09:56Z","timestamp":1655356196000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-022-05108-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,19]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["5108"],"URL":"https:\/\/doi.org\/10.1007\/s00296-022-05108-1","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,19]]},"assertion":[{"value":"25 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have declared no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}